Immunotherapy combo shows promise for rare sinus cancer
NCT ID NCT05925491
First seen Apr 17, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal tumors more effectively and with fewer side effects. About 28 adults with a rare, aggressive sinus cancer will receive the combination, then surgery, followed by more pembrolizumab. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SINONASAL UNDIFFERENTIATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Clinici Scientifici Maugeri
RECRUITINGPavia, Lombardy, 27100, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.